Table 1.
Baseline patient characteristics
| n = 15 | |
|---|---|
| Age (years) | 67.0 (65.0/75.5) |
| BMI (kg/m2) | 23.0 (20.7/25.7) |
| Fracture, n (%) | 9.0 (60.0) |
| History of family fracture, n (%) | 1.0 (7.1) |
| Smoking, n (%) | 0 (0) |
| Alcohol, n (%) | 1.0 (6.7) |
| Albumin (mg/dL) | 4.4 (4.3/4.4) |
| Calcium (mg/dL) | 9.3 (9.2/9.6) |
| Phosphate (mg/dL) | 3.6 (3.3/3.8) |
| Alkaline phosphatase (U/L) | 301.0 (288.5/336.0) |
| eGFR (mL/min) | 69.0 (62.0/90.0) |
| intact PTH (pg/mL) | 35.0 (26.0/63.5) |
| Bone turnover markers | |
| total P1NP (μg/dL) | 53.50 (40.00/91.60) |
| TRACP-5b (mU/dL) | 412.00 (385.50/581.50) |
| Areal BMD (g/cm2) measured by DXA | |
| Lumbar spine | 0.70 (0.66/0.77) |
| Femoral neck | 0.56 (0.49/0.59) |
| Total hip | 0.70 (0.63/0.74) |
| Volumetric BMD (mg/cm3) measured by QCT | |
| Central-vBMD | 56.90 (49.22/70.27) |
| Right side of PS-vBMD | 59.48 (52.94/82.25) |
| Left side of PS-vBMD | 60.33 (53.67/81.03) |
Data are expressed as median (Q1/Q3)
BMI body mass index, eGFR estimate glomerular filtration, PTH parathyroid hormone, P1NP N-terminal propeptide of type 1 procollagen, TRACP-5b tartrate-resistant acid phosphatase 5b, BMD bone mineral density, DXA dual energy X-ray absorptiometry, QCT quantitative computed tomography, PS-vBMD pedicle screw volumetric bone mineral density